Table 2.

Overall and disease-specific survival by HPV16 DNA and RNA detection

	Overall N	Oropharynx			Non-oropharynx
HPV16 (positive vs. negative)		n	Hazard ratiosa (95 % CI)	p value	n	Hazard ratiosa (95 % CI)	p value
Overall survival
HPV16 DNAb	176	57	0.37 (0.15–0.89)	0.03	119	0.83 (0.32–2.13)	0.70
HPV16 RNAc	203	67	0.35 (0.17–0.74)	<0.01	136	0.72 (0.36–1.44)	0.35
HPV16 combined definitiond	208	65	0.26 (0.09–0.72)	0.01	143	0.95 (0.37–2.43)	0.91
Disease-specific survival
HPV16 DNAb	176	57	0.10 (0.01–0.84)	0.03	119	0.51 (0.13–2.00)	0.36
HPV16 RNAc	203	67	0.13 (0.03–0.61)	<0.01	136	0.59 (0.20–1.72)	0.34
HPV16 combined definitiond	208	65	0.11 (0.01–0.86)	0.03	143	0.65 (0.16–2.59)	0.54

^aHazard ratios adjusted for age, sex, nodal stage, tumor size, primary treatment, smoking, drinking, and interaction term (HPV16*tumor site). See Supplemental Table 1 for hazard ratios of all variables

^bIncludes available data for HPV16 DNA detection only (79 % of total sample)

^cIncludes available data for HPV16 RNA detection only (91 % of total sample)

^dHPV16 is positive if DNA and RNA PCR detection are both positive. HPV16 is negative if either DNA or RNA PCR detection is negative. Missing data for RNA and DNA PCR detection is omitted